In the two groups of patients, the proportions of ≥2 lines of previous systemic therapy were 80.0% (24/30) vs 64.0% (16/25), the proportions of previous anti-PD-1/PD-L1 therapy were both 100% ...

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...

PRAGUE & BASEL, Switzerland & BOSTON--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present on June 1, 2024 (Developmental Therapeutics ...

Using ASCO ™ zero-emissions electric dump valves ... led to an increase in natural gas production. The valves also use 1.2 watts (W) of energy compared to a conventional electric retrofit ...

Results are being highlighted in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The Phase 1/2 ...

ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Kevin Zarrabi discussing the molecular characterization of STEAP1 and STEAP2 in advanced prostate cancer. STEAP 1 and 2 ...

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "On top of the preliminary data reported at 2024 ASCO and 2024 ESMO ... About IBI363 (First-in-class PD-1/IL-2 α-bias bispecific antibody ...

It is worth mentioning that Innovent's pipeline has a total of 8 oral presentations at this ASCO conference, representing approximately 2% of the conference's total oral presentations. PD-1/IL-2 ...

In all dose groups (N=32), the median PFS of smokers was longer than non-smokers: 5.3 (2.0, 7.0) vs 3.0 (1.6, 5.1 ... in the field of lung cancer at the ASCO conference. IBI363 shows remarkable ...